Celgene Corp (CELG)

112.31
0.35 0.31
NASDAQ : Health Care
Prev Close 112.66
Open 112.73
Day Low/High 111.63 / 113.36
52 Wk Low/High 92.98 / 137.54
Volume 3.53M
Avg Volume 5.02M
Exchange NASDAQ
Shares Outstanding 775.20M
Market Cap 88.08B
EPS 2.00
P/E Ratio 43.20
Div & Yield N.A. (N.A)

Latest News

5 Reasons Celgene Should Buy Biogen

5 Reasons Celgene Should Buy Biogen

A merger would be smart, profitable ... and attention-grabbing.

Biotech School: When Cellceutix CEO Rants About 'Criminal' Short, Smart Investors See Red Flags

Biotech School: When Cellceutix CEO Rants About 'Criminal' Short, Smart Investors See Red Flags

CEOs of troubled companies tend to launch public tirades against the 'evil' shorts. The rants are often a smokescreen meant to divert investors' attention from problems.

Allergan, Apple, Facebook: Doug Kass' Views

Allergan, Apple, Facebook: Doug Kass' Views

Doug Kass shares his thoughts on buying retail, and discusses why he's favoring the short side in a big way.

Celgene Could Skyrocket by 22% With Ease

Celgene Could Skyrocket by 22% With Ease

More upside could be on the way here.

Monday's Sights, Sounds and Biotech Buzz From the J.P. Morgan Healthcare Conference

Monday's Sights, Sounds and Biotech Buzz From the J.P. Morgan Healthcare Conference

The $5.2 billion takeout of Ariad Pharma was the biggest news from the closely followed healthcare conference.

Nasdaq Hits Records Even as Crude Selloff Sours Rest of Market

Nasdaq Hits Records Even as Crude Selloff Sours Rest of Market

A selloff in crude oil proves another roadblock in the Dow Jones Industrial Average's pursuit of 20,000.

Celgene Sees Much Higher Profits, but Wall Street Still Yawns

Celgene Sees Much Higher Profits, but Wall Street Still Yawns

Here's what the market chose to focus on instead.

Celgene Ups Revenue and Profit Projections for 2017, but Stock Falls

Celgene Ups Revenue and Profit Projections for 2017, but Stock Falls

Celgene executives have raised guidance for the year, but the stock retreated Monday.

Celgene Corporation Announces Preliminary 2016 Unaudited Results And 2017 Financial Guidance

Celgene Corporation Announces Preliminary 2016 Unaudited Results And 2017 Financial Guidance

Celgene Corporation (NASDAQ:CELG) today provided a business update as well as its preliminary 2016 unaudited results and financial guidance for 2017 at the 35 th Annual J.

Market Recon: Only the Tape Tells the Truth

Market Recon: Only the Tape Tells the Truth

It doesn't really matter where you think a stock should trade at.

Alphabet, Apple, Allergan: Doug Kass' Views

Alphabet, Apple, Allergan: Doug Kass' Views

Doug Kass shares his thoughts on the deepening of retail stocks' weakness and the Amazon Effect.

Here Are 6 Things to Watch Out for at J.P. Morgan's Healthcare Conference Next Week

Here Are 6 Things to Watch Out for at J.P. Morgan's Healthcare Conference Next Week

Next week the J.P. Morgan Healthcare Conference becomes the hottest spot in biotech and pharma.

Jim Cramer on the Problems With Buying Drug Stocks

Jim Cramer on the Problems With Buying Drug Stocks

Jim Cramer breaks down why it is so difficult to buy drug stocks right now.

Here's What to Look for at the J.P. Morgan Healthcare Conference

Here's What to Look for at the J.P. Morgan Healthcare Conference

The biggest annual event for biotech and pharma investors starts Monday with the kickoff of the J.P. Morgan Healthcare Conference in San Francisco.

What Biotech Investors Can Expect From the J.P. Morgan Health Care Conference 2017

What Biotech Investors Can Expect From the J.P. Morgan Health Care Conference 2017

Every January at 'JPM,' investors take the pulse of the biotech industry for the coming year.

Russell 2000 Paces Gains

I bought ProShares Ultra QQQ ETF and Tarena International and sold two-thirds of my Ross Stores.

Celgene Corporation To Announce Fourth Quarter And Full-Year 2016 Results On January 26, 2017

Celgene Corporation To Announce Fourth Quarter And Full-Year 2016 Results On January 26, 2017

Celgene Corporation (NASDAQ:CELG) will host a conference call and live audio webcast on Thursday, January 26, 2017 at 9 a.

17 Thoughts on Biotech Stocks to Kick Off 2017

17 Thoughts on Biotech Stocks to Kick Off 2017

Adam Feuerstein compiles a list of questions, thoughts, declarations, catalysts and observations about biotech stocks to help investors prepare for the year ahead.

Starbucks, Allergan, Amazon: Doug Kass' Views

Starbucks, Allergan, Amazon: Doug Kass' Views

Doug Kass shares his thoughts on how 2017 will be the year of 'the Dude.'

Doug Kass' Top Pick for 2017: Short QQQ

Doug Kass' Top Pick for 2017: Short QQQ

Kass' trade of the year for 2017 is to short the PowerShares QQQ Trust ETF.

My Top Pick for 2017: Short QQQ

My Top Pick for 2017: Short QQQ

Six reasons why the Nasdaq 100 ETF seems ready to pull back.

Allergan, Apple, Costco: Doug Kass' Views

Allergan, Apple, Costco: Doug Kass' Views

Doug Kass shares his thoughts on the post-fact investment world and delivers his verdict on Caterpillar.

'Mad Money' Lightning Round: Southwestern Energy, UnitedHealth, Celgene and More

'Mad Money' Lightning Round: Southwestern Energy, UnitedHealth, Celgene and More

Jim Cramer favors UnitedHealth over Cerner, and U.S. Concrete more than Cemex.

Jim Cramer's 'Mad Money' Recap: Don't Worry About a Little Market Detour

Jim Cramer's 'Mad Money' Recap: Don't Worry About a Little Market Detour

Get used to some down days, says Jim Cramer, but don't lose sight of the success for financial stocks.

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

TheStreet's biotech columnist offers his own report card on biotech stocks.